Literature DB >> 1143086

Acute renal failure in multiple myeloma.

R A Defronzo, R L Humphrey, J R Wright, C R Cooke.   

Abstract

1. The clinical manifestations, laboratory data and renal histologic features of acute renal failure occurring in 14 patients with multiple myeloma are reviewed and contrasted with the data from 29 previously reported cases. 2. Whereas other reports have stressed the role of intravenous pyelography and dehydration in the development of acute renal failure in multiple myeloma, the most common etiologic factor in our experience was hypercalcemia (7 patients). Other factors included potentially nephrotoxic antibiotics (3 patients) and volume depletion (2 patients). Intravenous pyelography could be clearly implicated in ony one patient. 3. The unusually high incidence of Bence Jones proteinuria in these patients is consistent with the possibility that Bence Jones protein excretion is associated with an increased susceptibility to renal injury. This could be due to an adverse effect of Bence Jones proteins on the renal tubules or their tendency to precipitate in tubular lumina during periods of reduced tubular flow. 4. The prognosis of patients with multiple myeloma who develop acute renal failure is poor; only 5 of our 14 patients survived the early period of acutely impaired renal function, and 4 of these subsequently died within 2 months. Preventive measures particularly the prompt correction of hypercalcemia and volume depletion, are the most important aspects of patient management.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1143086     DOI: 10.1097/00005792-197505000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  24 in total

1.  Successful treatment of myeloma kidney by diuresis and plasmaphoresis.

Authors:  T G Feest; P S Burge; S L Cohen
Journal:  Br Med J       Date:  1976-02-28

2.  Light chains and the kidney.

Authors:  J R Bradley; S Thiru; D B Evans
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

3.  Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies.

Authors:  Lorenzo Preda; Alberto Agazzi; Sara Raimondi; Carla Federica Lanfranchi; Rita Passerini; Albania Calvetta; Giovanni Martinelli; Massimo Bellomi
Journal:  Eur Radiol       Date:  2010-08-02       Impact factor: 5.315

4.  Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo.

Authors:  P W Sanders; G A Herrera; A Chen; B B Booker; J H Galla
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Electrophoretic study of the physico-chemical characteristics of Bence-Jones proteinuria and its association with kidney damage.

Authors:  M C Diemert; L Musset; O Gaillard; S Escolano; A Baumelou; F Rousselet; J Galli
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

6.  Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures.

Authors:  Maeve P Crowley; Vinitha N Prabhakaran; Oonagh M Gilligan
Journal:  Pathol Oncol Res       Date:  2017-09-13       Impact factor: 3.201

7.  Amyloid casts within renal tubules: a singular finding in myelomatosis.

Authors:  M Melato; G Falconieri; E Pascali; A Pezzoli
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

8.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

9.  Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins.

Authors:  P W Sanders; B B Booker; J B Bishop; H C Cheung
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

10.  Should patients with renal failure associated with myeloma be dialysed?

Authors:  R A Coward; N P Mallick; I W Delamore
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.